Some patients using GLP-1 medications for weight management have reported hair thinning or alopecia, particularly with semaglutide (Wegovy) and tirzepatide (Zepbound)
35 Notably, this protective effect appears to be dependent on the duration of treatment, with only a GLP-1RA treatment period exceeding 52 weeks being associated with decreased fracture risk
: #ObesityCare #GLP1 #Enobosarm #BodyComposition #LeanMassPreservation #ClinicalTrials #BiotechNews #MetabolicHealth #SARM #WeightManagement #HealthTech #Veru #PrecisionMedicine #DEXA #FunctionalOutcomes Harry Fisch MD Mitchell Steiner, MD, FACS, To view or add a comment, sign in 2025 Exercise Evidence Colleagues, new Endocrine Reviews article on exercise + obesity DATA ALIGNS #ADASOC2026: 150 min/week validated - confirms 20% insulin sensitivity, 0.8% HbA1c #AHA/ACC: Exercise for CVD risk - confirmed across all intensities #AASLD:Exercise first-line for MASLD - validated in just 2 weeks EVIDENCE AHEAD OF GUIDELINES: GLP-1 RA + exercise:60% less regain Bariatric surgery protocols: 5-year pre/post-op data Benefits independent of weight loss:Underemphasized in current standards KEY DATA - COMBINATION THERAPY: GLP-1 RAs + Exercise: Liraglutide + vigorous exercise 4x/week: - 9.5kg loss at 1 year - Only 2.5kg regain vs
For people over 50, this contributes directly to the classic post-meal energy crash, creeping weight gain around the midsection, and the gradual loss of muscle mass associated with sarcopenia
A 2 mg dose is 2 10 = 0.2 mL, which is 20 units on a U-100 insulin syringe
Ahrn B (2019) DPP-4 inhibition and the path to clinical proof
